Antigen expression patterns reflecting genotype of acute leukemia

Leukemia

Volumn 16, Issue 7, 2002, Pages 1233-1258

  Hrusak O ^a   Porwit MacDonald, A ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chromosomes; Cytogenetics; Flow cytometry; Immunophenotype; Leukemia

Indexed keywords

AML PROTEIN; BCR ABL PROTEIN; CD11 ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD22 ANTIGEN; CD24 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PBX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER CLASSIFICATION; CANCER SCREENING; CELL FUNCTION; CELL LINEAGE; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 4; CHROMOSOME TRANSLOCATION 5; CHROMOSOME TRANSLOCATION 8; CHROMOSOME TRANSLOCATION 9; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; DISEASE ASSOCIATION; FLOW CYTOMETRY; FUSION GENE; GENE REARRANGEMENT; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRISOMY 8;

EID: 0036049687     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402504     Document Type: Review

References (251)

1. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial
2. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: A Nordic series comparing two treatment periods
3. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA
4. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias
5. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements
6. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients abnormalities of chromosome band 11q23
7. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1
8. MLL gene rearrangements, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia
9. Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein
10. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: Correlation with specific genotype. I. ETV6/AML1 ALLs identification
11. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression
12. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors
13. Proposals for the immunological classification of acute leukemias
14. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: Implications for minimal residual disease studies
15. Analysis of Wilms tumor gene (WT1) expression in acute leukemia patients with special reference to the differential diagnosis between eosinophilic leukemia and idiopathic hypereosinophilic syndromes
16. Unusual immunophenotypes in acute leukaemias: Incidence and clinical correlations
17. The immunologic detection of minimal residual disease in acute leukemia
18. Acute myeloid leukemias expressing lymphoid-associated antigens: Diagnostic incidence and prognostic significance
19. Characterization of aberrant phenotypes in acute myeloblastic leukemia
20. Expression of unusual immunophenotype combinations in acute myelogenous leukemia
21. Flow cytometric characterization of acute myeloid leukemia. Significance of light scattering properties
22. Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells
23. Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38- hematopoietic stem cells
24. Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry
25. Myeloperoxidase expression in CD34+ normal human hematopoietic cells
26. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development
27. Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis
28. Immunophenotype of c-kit cells in normal human bone marrow: Implications for the detection of minimal residual disease in AML
29. Flow cytometric analysis of normal B cell differentiation: A frame of reference for the detection of minimal residual disease in precursor-B-ALL
30. BIOMED-1 concerted action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)
31. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations
32. BIOMED-I concerted action report: Flow cytometric immuno-phenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-I Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: Standardization and Clinical Evaluation
33. Immuno-phenotypical detection of minimal residual disease in acute leukemia
34. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age
35. Cytogenetic heterogeneity in t(11;19) acute leukemia: Clinical, hematological and cytogenetic analyses of 48 patients - Updated published cases and 16 new observations
36. Infant acute lymphoblastic leukaemia with t(11;19)
37. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
38. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia
39. Cytogenetic studies of infant acute lymphoblastic leukemia: Poor prognosis of infants with t(4;11) - A report of the Children's Cancer Group
40. TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood
41. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia
42. TEL/AML1 positivity in childhood ALL: Average or better prognosis?
43. Significantly lower relapse rate for TEL/AML1-positive ALL
44. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation
45. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse
46. Prognostic importance of chromosome number in 136 untreated children with acute lymphoblastic leukemia
47. Prognostic impact of bone marrow karyotype in childhood acute lymphoblastic leukaemia: Swedish experiences 1986-91
48. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study
49. Prognostic implication of hyperdiploidy as based on DNA flow cytometric measurement in childhood acute lymphocytic leukemia - A multicenter study
50. Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia
51. Phenotypic and karyotypic properties of hyperdiploid acute lymphoblastic leukaemia of childhood
52. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials CoALL-05-92
53. Acute lymphoblastic leukemia
54. Acute lymphoblastic leukemia in children
55. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
56. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
57. Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia
58. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
59. Prognostic factors for selecting curative therapy for adult acute myeloid leukemia
60. Treatment outcome with chemotherapy in acute promyelocytic leukemia: The Southwest Oncology Group (SWOG) experience
61. All-trans-retinoic acid in acute promyelocytic leukemia
62. Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia
63. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): Univariate and recursive partitioning analysis of patients Oncology Group (POG) Study 8821
64. Hematological malignancies with a deletion of 11q23: Cytogenetic and clinical aspects. European 11q23 Workshop participants
65. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: Existence of different entities with 11q23 breakpoint
66. Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: Report from a t(1;22) study group
67. Hematologic malignancies with t(4;11)(q21;q23) - A cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants
68. Hematological malignancies with t(9;11)(p21-22;q23) - A laboratory and clinical study of 125 cases. European 11q23 Workshop participants
69. Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: Report of three cases and review of the literature
70. Acute lymphoblastic leukemia occurring as a second malignancy: Report of a case and review of literature
71. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop
72. Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias
73. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy
74. General Report on the European Union Concerted Action Workshop on 11q23
75. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89
76. NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic cases
77. NG2 proteoglycan-binding peptides target tumor neovasculature
78. PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse
79. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells
80. Generation of oligodendroglial progenitors in acute inflammatory demyelinating lesions of the rat brain stem is associated with demyelination rather than inflammation
81. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients excellent prognosis
82. T(12;21): A new recurrent translocation in acute lymphoblastic leukemia
83. The role of TEL fusion genes in pediatric leukemias
84. Impact of TEL/AML1-positive patients on age distribution of childhood acute lymphoblastic leukemia in Czech Republic
85. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multi-center therapy trials
86. TEL/AML1 fusion gene is a rare event in adult acute lymphoblastic leukemia
87. Two cases of very late relapsing ALL carrying the TEL:AML1 fusion gene
88. The majority of myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts
89. Aberrant expression of KOR-SA3544 antigen in childhood acute lymphoblastic leukemia predicts TEL-AML1 negativity
90. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: A Pediatric Oncology Group study
91. Are we ready to curtail testing for TEL/AML1 fusion?
92. DNA index and %S-phase cells determined in acute lymphoblastic leukemia of children: A report from studies ALL V, ALL VI, and ALL VII (1979-1991) of the Dutch Childhood Leukemia Study Group and The Netherlands Workgroup Genetics and Cytogenetics
93. Sex differences in prognosis for children with acute lymphoblastic leukemia
94. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: A distinct biological entity with a marked propensity to undergo apoptosis
95. Clinical significance of cytogenetic findings at diagnosis and in remission in childhood and adult acute lymphoblastic leukemia: Experience from India
96. Leukemia-associated changes identified by quantitative flow cytometry: I. CD10 expression
97. Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: A Pediatric Oncology Group study
98. Cytogenetic abnormalities associated with the t(12;21): A collaborative study of 169 children with t(12;21)-positive acute lymphoblastic leukemia
99. Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood
100. Tetraploid or near-tetraploid clones characterized by two 8;21 translocations and other chromosomal abnormalities in two patients with acute myeloblastic leukemia
101. Near-tetraploid poorly differentiated acute myeloid leukemia M0 diagnosed by short-term cultures with a phorbol ester TPA
102. Two new cases of near-tetraploidy in adult acute myeloid leukemia
103. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
104. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
105. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
106. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype
107. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study
108. Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: Results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993
109. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children's Cancer Group
110. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor precursor ALL
111. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: A pediatric oncology group report of 343 cases
112. CD34 antigen expression in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
113. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia
114. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
115. A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity
116. The KOR-SA3544 antigen predominantly expressed on the surface of Philadelphia chromosome-positive acute lymphoblastic leukemia cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed leukemia cells
117. CD66 family Workshop Panel report
118. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells
119. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: Clinical features and molecular pathogenesis
120. Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1;19) chromosome abnormalities in a consecutive group of 141 adult with acute lymphoblastic leukemia
121. Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia
122. A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice
123. Expression of the E2A-PBX1 fusion transcripts in t(1;19)(q23;p13) and der(19)t(1;19) at diagnosis and in remission of acute lymphoblastic leukemia with different B lineage immunophenotypes
124. Heterogeneity of t(1;19)(q23;p13) acute leukaemias
125. A case of mature B-cell ALL with coexistence of t(1;19) and t(14;18) and expression of the E2A/PBX1 fusion gene
126. 1;19 translocation in human meningioma
127. Expression of identical E2A/PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia
128. Correlation of cytoplasmic Ig mu (C mu) and E2A-PBX1 fusion transcripts in t(1;19) B lineage ALL: Discrepancy in C mu detection by slide immunofluorescence and flow cytometry
129. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: Implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: A Pediatric Oncology Group study
130. Hyperdiploidy and E2A-PBX1 fusion in an adult with t(1;19)+ acute lymphoblastic leukemia: Case report and review of the literature
131. New recurring chromosomal translocations in childhood acute lymphoblastic leukemia
132. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia
133. Rearrangement of the c-myc proto-oncogene locus in a cell line of T-lymphoblastic origin
134. Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias
135. Gene encoding the alpha chain of the T-cell receptor is moved immediately downstream of c-myc in a chromosomal 8;14 translocation in a cell line from a human T-cell leukemia
136. Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: The Pediatric Oncology Group experience
137. Morphologic characteristics of acute lymphoblastic leukemia (ALL) with abnormalities of chromosome 8, band q24
138. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia
139. Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia
140. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia
141. Frequency and DNA sequence of tal-1 rearrangement in children with T-cell acute lymphoblastic leukemia
142. Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes
143. SIL-TAL1 deletion in T-cell acute lymphoblastic leukemia
144. Clinical significance of TAL1 gene alteration in childhood T-cell acute lymphoblastic leukemia and lymphoma
145. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: A Pediatric Oncology Group study
146. TAL1 expression does not occur in the majority of T-ALL blasts
147. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: A report from the Children's Cancer Group
148. Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage
149. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies
150. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia
151. Is translocation (8;21) a 'favorable' cytogenetic rearrangement in acute myeloid leukemia?
152. Fourth International Workshop on Chromosomes in Leukemia 1982: Translocation (8;21)(q22;q22) in acute nonlymphocytic leukemia
153. Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells
154. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: Correlation with cytogenetics, morphology and immunophenotype
155. Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia
156. The 8;21 chromosome translocation in acute myeloid leukemia is always detectable by molecular analysis using AML1
157. 8;21 translocation in acute granulocytic leukaemia: Cytological, cytochemical and clinical features
158. Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia
159. Cytologic characterization and significance of normal karyotypes in t(8;21) acute myeloblastic leukemia
160. Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21)
161. Cellular characteristics of acute myeloblastic leukemia associated t(8;21)(q22;q22)
162. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children
163. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: Frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34
164. Immunophenotypic features of t(8;21) (q22;q22) acute myeloid leukemia in adults
165. Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21)
166. Immunophenotypic analysis enables the correct prediction of t(8:21) in acute myeloid leukaemia
167. Morphologic, immunologic, and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: A report from the Childrens Cancer Group
168. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87
169. The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance
170. Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: A prospective study of 432 patients
171. Acute myeloid leukemia M2 and t(8;21)(q22;q22) with an unusual myeloperoxidase (+), CD13 (-), CD14 (-), and CD33 (-)
172. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22)
173. Expression of CD7 antigen precludes t(8;21)(q22;q22) chromosome aberration in acute myeloblastic leukemia
174. Analysis of CD7 expression in acute myelogenous leukemia: Martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance
175. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia
176. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia
177. Acute promyelocytic leukemia
178. Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia
179. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia
180. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group
181. A new morphologic classification system for acute promyelocytic distinguishes cases with underlying PLZF/RARA gene rearrangements. Francais de Cytogenetique Hematologique, UK Cancer Cytogenetics Group Community-Concerted Action Molecular Cytogenetic Diagnosis in Haematological Malignancies
182. Diagnostic approaches to acute promyelocytic leukaemia
183. Comprehensive review of adult acute myelogenous leukemia: Cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings
184. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements
185. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia
186. Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: A comparative study of Australian and Japanese adult cases
187. Light scatter and immunophenotypic characteristics of blast cells in typical acute promyelocytic leukemia and its variant
188. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation
189. Acute promyelocytic leukaemia: Epidemiology and risk factors. A report of the GIMEMA Italian archive of adult acute leukaemia
190. Rearrangements of the RAR-alpha gene in acute promyelocytic leukaemia: Correlations with morphology and immunophenotype
191. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses
192. Unique immunophenotype of acute promyelocytic leukaemia as defined by and CD68 antibodies
193. Immunophenotype of adult and childhood acute promyelocytic leukaemia: Correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases
194. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint
195. Immunological definition of acute promyelocytic leukemia (FAB M3): A study of 39 cases
196. The immunophenotype of adult acute myeloid leukemia: High frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities
197. PML/RAR alpha APL with undifferentiated morphology and stem cell immunophenotype
198. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia
199. CD2 expression and the PML-RAR gene
200. Microgranular variant of acute promyelocytic leukemia in children
201. CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?
202. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy
203. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML)
204. Cytogenetics of childhood acute nonlymphocytic leukemia
205. Molecular pathogenesis of the chromosome 16 inversion in the M4EO subtype of acute myeloid leukemia
206. Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo
207. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association
208. Acute nonlymphocytic leukemia with marrow eosinophilia and chromosome 16 abnormality: A report of 18 cases
209. The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: A 12-year study (1970-1982)
210. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance
211. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression
212. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes
213. Acute myeloid leukemia with 11q23 translocations: Myelomonocytic immunophenotype by multiparameter flow cytometry
214. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes
215. Characterization of acute myeloid leukemia with MLL rearrangements - No increase in the incidence of coexpression of lymphoid-associated antigens on leukemic blasts
216. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia
217. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children
218. The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: A Pediatric Oncology Group Study
219. Nonrandom t(1;22)(p12-p13;q13) in acute megakaryocytic malignant proliferation
220. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia
221. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia
222. Megakaryoblastic leukemia and Down's syndrome: A review
223. Leukemias with megakaryoblastic involvement: Clinical, hematologic, and immunologic characteristics
224. Phenotypic and genotypic heterogeneity in infant acute leukemia. II. Acute nonlymphoblastic leukemia
225. Megakaryoblastic acute leukemia: Identification by the ultra-structural demonstration of platelet peroxidase
226. Myelodysplasia and acute myelogenous leukemia in Down's syndrome
227. Acute megakaryocytic leukemia: The Eastern Cooperative Oncology Group experience
228. Spontaneous remission of congenital acute nonlymphoblastic leukemia with normal karyotype in twins
229. Immunophenotype of a transient myeloproliferative disorder in a newborn with trisomy 21
230. Transient myeloproliferative disease of the newborn: Case report with placental, cytogenetic, and flow cytometric findings
231. Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome
232. Acute leukemia and the transient myeloproliferative disorder associated with Down syndrome: Morphologic, immunophenotypic and cytogenetic manifestations
233. D.K. Is trisomy 11 another nonrandom chromosomal anomaly in acute nonlymphocytic leukemia and myelodysplastic syndromes?
234. Karyotypic patterns in chronic myeloproliferative disorders: Report on 74 cases and review of the literature
235. Trisomy 11: An association with stem/progenitor cell immunophenotype
236. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: The Eastern Cooperative Oncology Group experience
237. Molecular and phenotypic spectrum of de novo Philadelphia positive acute leukemia
238. Characterization of Philadelphia-chromosome-positive acute leukemia by clinical, immunocytochemical, and gene analysis
239. A de novo Philadelphia chromosome-positive acute mixed-lineage leukemia with both major and minor BCR/ABL mRNA transcripts
240. Successive transformation of chronic myelomonocytic leukaemia into acute myeloblastic then lymphoblastic leukaemia, both with minor-bcr rearrangement
241. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients
242. Chromosomal aberrations characteristic for sAML/sMDS are not detectable by random screening using FISH in peripheral blood-deriyed grafts used for autologous transplantation
243. Childhood monosomy 7: Epidemiology, biology, and mechanistic implications
244. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7
245. Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia
246. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: The significance of the stem-cell glycoprotein CD34 (My10)
247. Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML
248. A case of congenital leukemia with monosomy 7
249. T(5;7)(q34;q21) in acute megakaryoblastic leukemia associated with Down syndrome
250. Reply: Immunophenotypic prediction of TEL-AML1 rearrangement in childhood ALL
251. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia